RemeGen's profit turnaround and new drug list inclusion drive gains
Essential medicines list inclusion RemeGen's innovative drugs were added to China's 2026 National Essential Medicines List, which should boost sales volume and long-term standardized treatment. This expands the patient base and supports revenue growth.
This is a new regulatory catalyst that directly increases demand for RemeGen's products.
Share buyback plan RemeGen announced a 25-50 million yuan share buyback, part of a broader wave of central enterprise buybacks. This signals management confidence and can support the stock price by reducing shares outstanding.
It shows insider confidence and provides a capital market support mechanism.
Profit turnaround expected RemeGen expects first-half 2026 net profit of about 4.7 billion yuan, swinging from a loss to a profit. This significant improvement reflects strong business performance and boosts investor confidence.
It is a major financial milestone that directly impacts valuation and sentiment.
Sector momentum and licensing deals Innovative drug stocks rallied, with sector out-licensing deals reaching $99.7 billion in H1 2026. RemeGen's improved results were highlighted, drawing investor attention to the sector's growth potential.
It shows broader industry tailwinds that can lift RemeGen's stock through increased sector investment.